Lucira Health Inc Revenue Growth Rates (LHDX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Lucira Health Inc   (NASDAQ: LHDX)
 

LHDX's Revenue Growth by Quarter and Year

Lucira Health Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LHDX Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September 34.39
2nd Quarter June 26.15
1st Quarter March 90.47
FY 151.01





LHDX Revenue third quarter 2022 Y/Y Growth Comment
Lucira Health Inc reported Revenue surge of 157.6% year on year in the third quarter 2022, to $ 34.39 millions, this is lower than Lucira Health Inc 's recent average Revenue surge of 723.71%.

According to the results reported in the third quarter 2022, Lucira Health Inc achieved the best Revenue growth in In Vitro & In Vivo Diagnostic Substances industry. While Lucira Health Inc ' s Revenue doubling of 157.6% ranks overall at the positon no. 241 in the third quarter 2022.


LHDX Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - 22607.41 % - -
3rd Quarter September 157.6 % - - -
2nd Quarter June 110.21 % - - -
1st Quarter March 1901.55 % - - -
FY   - 33833.33 % - -

Financial Statements
Lucira Health Inc 's third quarter 2022 Revenue $ 34.39 millions LHDX's Income Statement
Lucira Health Inc 's third quarter 2021 Revenue $ 13.35 millions Quarterly LHDX's Income Statement


LHDX Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 359.25 % - -
3rd Quarter September 31.51 % 7.32 % - -
2nd Quarter June -71.1 % 175.22 % - -
1st Quarter March 47.56 % 1574.07 % - -
FY (Year on Year)   - 33833.33 % - -


Back to LHDX Growth rate Comparisons >> Back to LHDX Growth rate Comparisons >>


Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #1
Healthcare Sector #73
Overall #241

Revenue Y/Y Growth Statistics
High Average Low
1903.41 % 723.71 % 110.19 %
(Mar 31 2022)   (Jun 30 2022)
Revenue third quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #1
Healthcare Sector #73
Overall #241
Revenue Y/Y Growth Statistics
High Average Low
1903.41 % 723.71 % 110.19 %
(Mar 31 2022)   (Jun 30 2022)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Lucira Health Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1578.81 % 304.1 % -71.1 %
(Mar 31 2021)  


LHDX's III. Quarter Q/Q Revenue Comment
Lucira Health Inc achieved in the III. Quarter 2022 below company average Revenue jump of 31.51% quarter on quarter, to $ 34.39 millions.

III. Quarter 2022 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 7.32% in the III. Quarter a year ago.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Lucira Health Inc 's Revenue growth quarter on quarter, overall rank is 525.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #132
Overall #525
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #132
Overall #525
Revenue Q/Q Growth Statistics
High Average Low
1578.81 % 304.1 % -71.1 %
(Mar 31 2021)  


LHDX's III. Quarter Q/Q Revenue Comment
Lucira Health Inc achieved in the III. Quarter 2022 below company average Revenue jump of 31.51% quarter on quarter, to $ 34.39 millions.

III. Quarter 2022 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 7.32% in the III. Quarter a year ago.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Lucira Health Inc 's Revenue growth quarter on quarter, overall rank is 525.


Lucira Health Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 212.32 $ 191.28 $ 177.57 $ 91.62 $ 0.00
Y / Y Revenue Growth (TTM) 594.35 % - - - -
Year on Year Revenue Growth Overall Ranking # 67 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 11 % 7.72 % 93.82 % 199.61 % -
Seq. Revenue Growth (TTM) Overall Ranking # 355 # 900 # 43 # 0 # 0


Cumulative Revenue growth Comment
With 594.35% annual Revenue growth, Lucira Health Inc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2022.

Among companies within the Healthcare sector 12 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 67.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 2
Healthcare Sector # 13
Overall # 67

Revenue TTM Y/Y Growth Statistics
High Average Low
594.35 %
 594.35 %
594.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 76
S&P 500 # 355
Cumulative Revenue growth Comment
With 594.35% annual Revenue growth, Lucira Health Inc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2022.

Among companies within the Healthcare sector 12 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 67.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 2
Healthcare Sector # 13
Overall # 67

Revenue TTM Y/Y Growth Statistics
High Average Low
594.35 %
594.35 %
594.35 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 2
Sector # 76
S&P 500 # 355




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LHDX's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Mirum Pharmaceuticals Inc 275.60%$ 275.600 millions
Evofem Biosciences Inc 272.14%$ 272.138 millions
Fresh Tracks Therapeutics Inc 268.18%$ 268.182 millions
Talis Biomedical Corporation265.14%$ 265.138 millions
Biorestorative Therapies Inc 262.50%$ 262.500 millions
Vir Biotechnology Inc 261.49%$ 261.486 millions
Igc Pharma Inc 260.71%$ 260.714 millions
Arvinas Inc 257.57%$ 257.574 millions
Arcus Biosciences Inc 254.94%$ 254.941 millions
Ideaya Biosciences Inc 230.87%$ 230.871 millions
Agape Atp Corporation229.81%$ 229.806 millions
Intra cellular Therapies Inc 223.63%$ 223.634 millions
Pear Therapeutics Inc 211.44%$ 211.442 millions
Revolution Medicines Inc 204.81%$ 204.814 millions
Harpoon Therapeutics Inc 203.68%$ 203.680 millions
Scynexis Inc 201.74%$ 201.744 millions
Tenon Medical Inc 197.14%$ 197.143 millions
Vbi Vaccines Inc196.26%$ 196.262 millions
Sutro Biopharma Inc 195.26%$ 195.257 millions
Statera Biopharma Inc fka Cytocom Inc 183.48%$ 183.475 millions
Bolt Biotherapeutics Inc 180.85%$ 180.851 millions
Rennova Health Inc 179.73%$ 179.728 millions
Hoth Therapeutics Inc 177.78%$ 177.775 millions
Geron Corporation172.48%$ 172.477 millions
Xeris Biopharma Holdings Inc 168.76%$ 168.761 millions
Albireo Pharma inc 168.34%$ 168.341 millions
Comera Life Sciences Holdings Inc 167.56%$ 167.565 millions
Aligos Therapeutics Inc 167.14%$ 167.144 millions
Macrogenics Inc 166.47%$ 166.467 millions
Celldex Therapeutics inc 166.01%$ 166.013 millions


About Lucira Health Inc Revenue Growth Rates (LHDX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Lucira Health Inc (CIK 1652724).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-22-025095
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Lucira Health Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.